Compare EPAM Systems Inc (EPAM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? EPAM Systems Inc trades at $98.88 (market cap $5.15B), while Vertex Pharmaceuticals Incorporated trades at $529.79 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 26.1× EPAM Systems Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| EPAM | VRTX | |
|---|---|---|
Market Cap | $5.15B | $134.25B |
Sector | Technology | Health |
52-Week High | $221.40 | $529.65 |
52-Week Low | $76.04 | $376.62 |
Enterprise Value | $4.52B | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM trades at $98.20, up 0.85% on the day, but remains in a bearish technical trend with support near $96 and resistance at $99. The company reported strong Q2 2026 earnings of $3.38 per share, beating estimates, but lowered its full-year revenue guidance due to slower North American growth. Valuation metrics appear attractive with a P/E of 13.55 and P/S of 0.97, while profitability remains solid with a net income margin of 7.15%.
The outlook is mixed: analyst consensus is bullish with a $117.27 price target, but near-term headwinds from reduced revenue guidance and bearish technical signals pose risks. The stock offers value based on fundamentals, but investor sentiment is cautious following the guidance cut, requiring close monitoring of North American demand trends and AI partnership execution for sustained upside.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
